Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3295668 + Midazolam |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3295668 | LY3295668 erbumine|AK-01|AK 01|LY-3295668|LY 3295668 | Aurka Inhibitors 27 | LY3295668 selectively inhibits Aurora A kinase (AURKA), potentially resulting in increased apoptosis and decreased proliferation of tumor cells, and inhibition of tumor growth (PMID: 31530649). | |
| Midazolam | Dormicum | Dea No. 2884 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03955939 | Phase I | LY3295668 + Midazolam LY3295668 | A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | Completed | USA | BEL | 0 |